LUCIANA PARENTE COSTA SEGURO
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina
62 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 62
conferenceObject Induction of Lupus Nephritisin in Real Situation: Cyclophosphamide or Mycophenolate Mofetil?(2017) MUNHOZ, Gabriela; LACERDA, Maira; LOPES, Michelle; BORBA, Eduardo Ferreira; SEGURO, Luciana; BONFA, EloisaconferenceObject BASELINE CHARACTERISTICS OFA LONGITUDINAL, MULTINATIONAL, MULTIETHNIC STUDYOF LUPUS PATIENTS, WITH ORWITHOUT LUPUS NEPHRITIS(2023) NIETO, Romina; QUINTANA, Rosana; BORBA, Eduardo; HERNANDEZ, Lucia; FERNANDEZ, Diana; MAURELLI, Laura; ALBA, Paula; BORDON, Florencia; ARIZPE, Fernando; BERBOTTO, Guillermo; SERRANO, Rosa; BERTOLACCINI, Maria; KERSBERG, Eduardo; GARGIULO, Maria; RODRIGUEZ, Anabella; BARBOSA, Vitalina; GASPARIN, Andrese; CAVALCANTI, Fernando; ALVES, Laissa; PARENTE, Luciana; OLIVEIRA, Lucas de; NEIRA, Oscar; MASSARDO, Loreto; AROCA, Gustavo; NIETO, Ivana; MENDEZ, Paul; IGLESIAS, Antonio; ZUNIGA, Andres; VERA, Olga; PEREZ, Mario; NARES, Eduardo; AMEZCUA, Luis; GONZALEZ, Yelitza; GONZALEZ, Octavio; GALARZA, Dionicio; VAZQUEZ, Carolina; BARRIOS, Marcelo; LINARES, Magaly; REATEGUI, Cristina; QUIROS, Ana; POLANCO, Teresandris; PIZZAROSSA, Carina; REBELLA, Martin; CRESPO, Maria; DANZA, Alvaro; BONFA, Eloisa; ALARCON, Graciela; ZAZZETTI, Federico; ORILLION, Ashley; SBARIGIA, Urbano; ESTEL, Guillermo PonsconferenceObject EARLY AND LATE ONSET BIOPSY-PROVEN LUPUS NEPHRITIS WITHOUT OTHER ASSOCIATED AUTOIMMUNE DISEASES: SEVERITY AND LONG-TERM OUTCOME(2018) LOPES, M.; SANTOS, L.; SEGURO, L.; BONFA, E.conferenceObject CLINICAL AND SEROLOGICAL COMPARATIVE ANALYSIS OF SYSTEMIC SCLEROSIS WITH OR WITHOUT OVERLAP SYNDROMES IN A LARGE BRAZILIAN COHORT(2014) SILVA, C. M.; PASOTO, S. G.; VIANA, V. S.; SEGURO, L. P. C.; ANDRADE, D. C. O.; BONFA, E.; SAMPAIO-BARROS, P. D.conferenceObject Bone Metabolism Impairment in Heart Transplant: Results from a Prospective Cohort Study(2019) SEGURO, Luis; PEREIRA, Rosa; SEGURO, Luciana; CAPARBO, Valeria; AVILA, Monica; MANGINI, Sandrigo; CAMPOS, Iascara; GAIOTTO, Fabio; MARCONDES-BRAGA, Fabiana; BACAL, Fernando- Chronic arthritis in systemic lupus erythematosus: distinct features in 336 paediatric and 1830 adult patients(2016) GORMEZANO, Natali W. S.; SILVA, Clovis A.; AIKAWA, Nadia E.; BARROS, Diego L.; SILVA, Mariana A. da; OTSUZI, Carini I.; KOZU, Katia; SEGURO, Luciana Parente; PEREIRA, Rosa M. R.; BONFA, EloisaThe objectives of this study are to assess the frequency of chronic arthritis and compare the clinical and laboratory features in a large population of childhood-onset systemic lupus erythematosus (cSLE) and adult-onset (aSLE) patients. This historical study evaluated 336 cSLE and 1830 aSLE patients. Chronic arthritis was defined as synovitis of at least 6 weeks of duration. Rhupus was characterised as the association of SLE and chronic inflammatory arthritis with erosion and positive rheumatoid factor. Jaccoud's arthropathy is a non-erosive subluxation leading to severe deformity of the hands and feet. Data were compared using Student's t test or the Mann-Whitney test for continuous variables. For categorical variables, differences were assessed by Fisher's exact test and Pearson chi-square. Frequencies of chronic arthritis were similar in cSLE and aSLE (2.4 vs. 3.8 %, p=0.261). The median time from disease onset to appearance of chronic arthritis was shorter in cSLE (0 vs. 10 years, p<0.001), and the median of age at chronic arthritis diagnosis was [10.8 (4.2-14.6) vs. 40 (21-67), p<0.001]. The children presented with more chronic polyarthritis than the adults (75 vs. 32 %, p=0.024), a higher median number of joints with arthritis [8.5 (118) vs. 3 (1-9), p=0.017] and a higher number of joints with limitation [1.5(0-24) vs. 0(0-4), p=0.004]. The chronic arthritis diagnosis frequencies of hepatomegaly (25 vs. 0 %, p=0.009), splenomegaly (25 vs. 0 %, p=0.009), pericarditis (25 vs. 0 %, p=0.009), nephritis (37 vs. 3 %, p=0.006), haematuria (37 vs. 1.4 %, p=0.002), lupus anticoagulant (40 vs. 1.6 %, p=0.012), anticardiolipin IgM (40 vs. 1.5 %, p=0.012) and median Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) [10.5(1-20) vs. 6(4-16), p=0.029] were higher in cSLE. Frequency of rhupus, (12 vs. 17 %, p=1.0), Jaccoud's arthropathy (0 vs. 17 %, p=0.343) and treatments were similar in cSLE and aSLE. We determined that chronic arthritis in SLE has distinct features in children, with very early onset, polyarticular involvement and association with active disease. We further demonstrated in this series that a proportion of chronic arthritis involvement in SLE is manifested as rhupus and Jaccoud's arthropathy.
- Increased visceral adipose tissue and altered adiposity distribution in premenopausal lupus patients: correlation with cardiovascular risk factors(2018) SEGURO, L. P. C.; PAUPITZ, J. A.; CAPARBO, V. F.; BONFA, E.; PEREIRA, R. M. R.Objective: Visceral adipose tissue (VAT) correlates with cardiovascular risk factors and has never been assessed in systemic lupus erythematosus (SLE). Our aim was to evaluate VAT in premenopausal SLE patients. Methods: Sixty-three premenopausal SLE patients and 186 age-matched healthy women were included. Demographic, anthropometric, disease and treatment parameters were evaluated. VAT was measured by dual X-ray absorptiometry (DXA) with APEX 4.0 software. Results: SLE patients had a disease duration of 5.25 +/- 3.80 years, SLEDAI activity score of 4.35 +/- 5.13, SLICC/ACR-DI of 0.70 +/- 0.80, current prednisone dose of 11.60 +/- 12.10 mg/day and cumulative glucocorticoid dose of 22.34 +/- 12.94 g. Overweight/obese SLE patients and controls had similar VAT parameters (p>0.05). Among individuals with BMI <25 kg/m(2), SLE patients and controls had similar weight, fat mass and fat percentage (p>0.05) but patients had higher values of VAT parameters (VAT mass: 260.60 +/- 117.23 vs. 194.77 +/- 71.42 g, p=0.001; VAT area: 54.05 +/- 24.30 vs. 40.40 +/- 14.82 cm(2), p=0.001; VAT volume: 281.75 +/- 126.81 vs. 210.61 +/- 77.29 cm(3), p=0.001) and trunk/limb fat mass ratio (0.78 +/- 0.21 vs. 0.67 +/- 0.12, p=0.002) compared to controls. In SLE, VAT area correlated with weight (r=0.66, p<0.001), non-HDL cholesterol (r=0.53, p<0.001), LDL cholesterol (r=0.48, p<0.001) and triglycerides (r=0.33, p=0.008), but not with disease duration, SLEDAI, SLICC/ACR-DI or current glucocorticoid use (p>0.05). Conclusion: This study provides original evidence that SLE is associated with increased VAT and altered adiposity distribution. The correlation with traditional risk factors for cardiovascular disease, independent of current glucocorticoid dose and disease activity, suggests the role of visceral fat as an additional tool for risk assessment in these young patients.
- Is there a cure for systemic lupus erythematosus?(2013) ROSARIO, C.; SEGURO, L.; VASCONCELOS, C.; SHOENFELD, Y.The morbidity and mortality of systemic lupus erythematosus (SLE) is a subject of intense relevance in the literature, yet descriptions of prolonged and sustained remissions or even cure are barely reported. In recent decades the life expectancy in SLE patients has improved, but the quality of life seems to be poor compared with other chronic diseases and with the general population. The immunopathogenesis of SLE is complex and not fully understood, so patients have been treated with nonspecific immunosuppressive therapies. But in recent years, because of advances in basic science, targeted therapies have been developed. Despite the progress made in treating SLE, currently a cure in SLE seems to be a myth. SLE it seems, remains incurable. A specific treatment has not emerged to directly abrogate a disease-specific autoimmune response. Relapsing manifestations and complications of treatment still remain important markers of morbidity. Lupus (2013) 22, 417-421.
conferenceObject Anti-beta 2GP1-Domain-1 Antibodies Are a Marker Of APS Severity(2013) AGMON-LEVIN, Nancy; SEGURO, Luciana; ROSARIO, Cristina; MAHLER, Michael; GATTO, Mariele; TOMER, Nir; LEON, Elaine P.; DORIA, Andrea; KOVACS, Laszlo; COSTEDOAT-CHALUMEAU, Nathalie; GILBURD, Boris; SHOENFELD, YehudaconferenceObject PERIPHERAL NERVOUS SYSTEM DISEASE IN SYSTEMIC LUPUS ERYTHEMATOSUS: THE ROLE OF PREDISPOSING CONDITIONS(2018) FARGETTI, S.; BONFA, E.; SHINJO, S. K.; PASOTO, S. G.; SEGURO, L. P. C.; LOPES, M. R. U.; GONCALVES, C. R.; BORBA, E. F.